COMMUNIQUÉS West-GlobeNewswire

New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease
20/03/2026
Findings underpin potential of Anavex’ lead candidate blarcamesine through its upstream mechanism of action and SIGMAR1-mediated autophagy restoration NEW YORK, March 20, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences [...]
The Ensign Group, Inc. Declares Quarterly Dividend of $0.0650 Per Share
20/03/2026
SAN JUAN CAPISTRANO, Calif., March 20, 2026 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign ™ group of companies, which invest in and provide skilled nursing and senior living [...]
Foundation Consumer Healthcare Sells Portion of Consumer Health Business
20/03/2026
Company Will Retain Flagship Brand, Plan B One-Step® PITTSBURGH, March 20, 2026 (GLOBE NEWSWIRE) -- Foundation Consumer Healthcare (FCH) announced today that it has entered into a definitive agreement to sell a portion [...]
Evidence of Efficacy and Safety of Deucrictibant for Prophylaxis and On-Demand Treatment of Hereditary Angioedema Attacks Published Back-to-Back in The Lancet Haematology
20/03/2026
Results from Phase 2 clinical studies, CHAPTER-1 and RAPIDe-1, provide evidence of viability of bradykinin B2 receptor antagonism in management of HAE ZUG, Switzerland, March 20, 2026 (GLOBE NEWSWIRE) -- Pharvaris ( [...]
Aquestive Therapeutics Announces New Role of Lori J. Braender and Appointment of Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer
20/03/2026
Thomas A. Zalewski, a Partner at Day Pitney LLP, appointed Chief Legal Officer and Chief Compliance Officer effective April 2, 2026 Lori J. Braender to remain in a non-executive role as Corporate Secretary after nearly [...]
Sironax Announces Upcoming Poster Presentation on NAMPT Activation
20/03/2026
NAD for Health conference, Copenhagen, March 23-25, 2026 WALTHAM, Mass., March 20, 2026 (GLOBE NEWSWIRE) -- Sironax, a global clinical-stage biotechnology company developing transformative therapies for [...]
Arch Biopartners Announces St. Michael’s Hospital Commences Patient Dosing in the Phase II CS-AKI Trial of LSALT Peptide
20/03/2026
TORONTO, March 20, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc . (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that St. Michael’s Hospital (SMH), part of Unity Health Toronto, has [...]
Cardiff Oncology to Host Key Opinion Leader Discussion Focusing on First-Line RAS-mutated Metastatic Colorectal Cancer
20/03/2026
SAN DIEGO, March 20, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today [...]
Human Appeal to deliver food aid to thousands of displaced civilians as part of initial response in Lebanon
20/03/2026
Ongoing conflict in the Middle East region has left thousands of families displaced in Lebanon, with an increase in food poverty, poor water sanitation and illness observed MANCHESTER, United Kingdom, March 20, 2026 ( [...]
On Match Day, ApolloMD Opens Applications for $5,000 Emergency Medicine Scholarship
20/03/2026
ATLANTA , March 20, 2026 (GLOBE NEWSWIRE) -- As medical students across the country learn where they will train during Match Day, ApolloMD is opening applications for its 2026 Emergency Medicine Scholarship . The annual [...]
The Cost of Bleeding Revealed: Menstruation costs £20,359 a lifetime, sparking calls for Government action
20/03/2026
New consumer research reveals women and people with cycles spend an average of £20,359 on menstruating in their lifetime More than 1 in 3 (37%) of respondents struggle to afford period products 39% cut back on other [...]
Galimedix Therapeutics presents strong pharmacokinetic profile of next-generation oral Alzheimer’s candidate at AD/PD™ 2026
20/03/2026
Kensington, MD, USA and Munich/Martinsried, Germany, March 20, 2026 (GLOBE NEWSWIRE) -- Prodrug of oral amyloid beta aggregation modulator demonstrated improved absorption characteristics, leading to substantially [...]
Telix choisit le Cyclone® KIUBE d’IBA pour étendre ses capacités de production aux États‑Unis
20/03/2026
Louvain ‑ la ‑ Neuve, Belgique, le 20 mars 2026 — IBA (Ion Beam Applications S.A., EURONEXT) , leader mondial des technologies d’accélérateurs de particules et premier fournisseur mondial de solutions de production de [...]
Telix selects IBA Cyclone® KIUBE to support manufacturing expansion in the U.S.
20/03/2026
Louvain-la-Neuve, Belgium– March 20, 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of radiopharmaceutical production solutions, [...]
Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipeline
20/03/2026
Proposed acquisition supports the Novartis oncology strategy in hormone receptor positive, human epidermal growth factor receptor two-negative (HR+/HER2-) breast cancer The lead asset, SNV4818, currently in a Phase 1/2 [...]
Cellectis Reports Full Year 2025 Financial Results and Provides a Business Update
20/03/2026
Pivotal Phase 2 with lasme-cel in r/r B-ALL (BALLI-01 trial) ongoing Phase 1: 83% ORR at RP2D and 100% ORR in the target Phase 2 population In target Phase 2 population: 100% of patients became eligible to transplant [...]
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity
19/03/2026
-- First and only FDA-approved therapy for the treatment of acquired hypothalamic obesity, a rare disease characterized by accelerated and sustained weight gain caused by hypothalamic injury or dysfunction – -- [...]
Cellectis publie ses résultats financiers du quatrième trimestre 2025 et de l’exercice 2025 et une mise à jour de ses activités
20/03/2026
Phase 2 pivot évaluant lasmé-cel dans la LAL-B en rechute ou réfractaire (étude BALLI-01) en cours Phase 1 : 83 % d’ORR à la dose RP2D et 100 % d’ORR dans la population cible de phase 2. Population cible de phase 2 : [...]
BioCardia to Host 2025 Financial Results and Corporate Update Conference Call on March 24, 2026
20/03/2026
SUNNYVALE, Calif., March 19, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it [...]

Pages